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Abstract
Purpose—The purpose is to address the problem in magnetic resonance imaging (MRI) of
contrast agent dilution.
Procedures—In situ magnetic labeling of cells and MRI were used to assess distribution and
growth of human hepatic stem cells (hHpSCs) transplanted into SCID/nod mice. It was done with
commercially available magnetic microbeads coupled to an antibody to a surface antigen,
Epithelial Cell Adhesion Molecule (EpCAM), uniquely expressed in the liver by hepatic
progenitors.
Results—We validated the microbead connection to cells and related MRI data to optical
microscopy observations in order to develop a means to quantitatively estimate cell numbers in the
aggregates detected. Cell counts of hHpSCs at different times post-transplantation revealed
quantifiable evidence of cell engraftment and expansion.
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Conclusions—This magnetic labeling methodology can be used with any antibody coupled to a
magnetic particle to target any surface antigen that distinguishes transplanted cells from host cells,
thus facilitating studies that define methods and strategies for clinical cell therapy programs.
Keywords
Magnetic resonance imaging (MRI); Cell labeling and tracking; Human hepatic stem cells; Cell
therapies; EpCAM
Introduction
The paucity of livers available for orthotopic liver transplantation results in an increased
interest in liver cell therapies in which suspensions of cells are injected into the livers of
patients with liver failure [1–3]. Cells obtained from a single donated liver are used to treat
multiple patients. Furthermore, the surgical procedures for cell therapies are less drastic,
potentially safer, and more economical than whole organ transplantation. As part of those
investigations, tracking methods are being explored for ways to follow what happens to the
donor cells after transplantation, both in terms of their final location within the host, and
whether they demonstrate expansion within the host tissues.
Labeling and noninvasive detection of transplanted cells are areas of active research in
molecular imaging, involving a variety of imaging modalities. For short-term (i.e., several
days to a few weeks) monitoring, cells pre-labeled with, for example, superparamagnetic
iron oxide (SPIO)-contrast agents, can be readily detected using MRI [4, 5]. The challenge
of the pre-labeling approach for all modalities is that the labels invariably fade over time as
their concentrations become diluted after each cell proliferation cycle. Alternative
approaches, ideally those that allow cells of interest and imaging labels to be transplanted or
administered separately, are needed for long-term cell tracking. A promising method has
been developed for positron emission tomography (PET) using a combination of cells
transfected with herpes simplex virus thymidine kinase and a special class of 18F radiolabels
[6–8]. However, techniques for post-transplantation labeling and detection remain elusive
for MRI, despite that the modality offers the advantages of better spatial resolution and
involves non-ionizing radiation.
Another challenge for all cell therapies from solid organs is that transplantation is done by a
vascular route, the current method of choice, and the cell populations engraft partially into
the target tissue but also distribute to other tissues. In the case of liver cell therapies, the
most common ectopic sites are the lungs and kidneys [2, 9,10]. This general issue is a major
factor in ongoing debates as to whether liver cell therapies should be done with mature
parenchymal cells or with hepatic progenitors [2, 11, 12]. The mature cells yield higher
engraftment, since they are larger (>20 μm), have a propensity for clumping leading to
aggregates of cells lodged within the sinusoids of the liver or in any tissue to which they go,
and the aggregates facilitate engraftment. The disadvantages are that the clumps increase the
risk of life-threatening emboli formation, especially in the lungs; the cells are highly
immunogenic resulting in the need for immunosuppressive therapy; and the effects of the
donor cells can be transient. By contrast subpopulations of hepatic progenitors are (1) small
(7–12 μm), (2) have lower engraftment (<5%) if injected by the portal vein and higher
engraftment (similar to that of mature cells) if injected into the hepatic artery, (3) rarely lead
to emboli, (4) have minimal or negligible immunogenicity, and (5) the cells that do engraft
into the liver offer long-term effects for the patient. The debates are spurring investigations
to identify better methods for transplantation, methods that can be assessed most easily if
there is the ability to track the cells after transplantation.
McClelland et al. Page 2













We are focused on developing forms of liver cell therapies utilizing human hepatic
progenitors, particularly human hepatic stem cells, hHpSCs, that are small (7–9 μm in
diameter) and give rise to hepatoblasts, hHBs,(10–12 μm in diameter), that in turn mature
into the hepatocytic and biliary cellular lineages of the liver. The hHpSCs can be
immunoselected from cell suspensions of fetal and postnatal livers of all donor ages as cells
positive for both epithelial cell adhesion molecule, EpCAM, and neural cell adhesion
molecule, NCAM [13,14]. The hHpSCs have been extensively characterized and conditions
identified for their ex vivo expansion and differentiation [14–19]. In addition to EpCAM and
NCAM, the hHpSCs express E-cadherin, CD133/1, albumin, Sonic and Indian hedgehog
proteins and their receptor, Patched, cytokeratins (CK 8, 18, and 19), telomerase protein
within the nucleus [17], have a metabolomics profile typical of stem cells [20], and are
negative for α-fetoprotein (AFP), intercellular adhesion molecule (ICAM-1), and all forms
tested of P450s. They are negative also for markers of hemopoietic cells (CD34, CD38,
CD14, CD45, CD90, glycophorin A), endothelial cells (CD31, Von Willebrand Factor,
VEGFr, CD146) and mesenchymal cells (desmin, α-smooth muscle actin, vitamin A,
CD146) [13,19].
Transplantation of hHpSCs must include strategies for tracking them in vivo to (1) monitor
cells at a designated site, (2) define rigorously the cell seeding densities, (3) track cell
integration within the host tissues, and (4) assess cell proliferation of the transplanted cells
within the liver. Here we present a method for in vivo cell MRI tracking enabling non-
invasive monitoring of the hHpSCs after transplantation. The methods identified consist of
marking the cells, pre- and/or post-cell transplantation, with magnetic nanoparticles coupled
to a surface antigen antibody that can distinguish transplanted cells from host cells. The
transplanted hHpSCs were detected by MRI signals that were confirmed and calibrated
against in vitro signal responses utilizing established cell spheroid aggregates with known
cell numbers. A major novelty of the current study is the detection of transplanted cells with
MRI contrast agents administered after transplantation, which paves the way for monitoring
cell distribution and growth in long term studies.
Materials and Methods
Human Fetal Livers
Livers from human fetuses between 16–20 weeks gestational age were obtained from an
accredited agency (ABR) within 18 hours of isolation and arrived in a medium, Kubota’s
Medium (KM), found effective for hepatic progenitors [21], supplemented with 5% fetal
bovine serum, and maintained at 4°C.
Media and Solutions
All media and buffers were sterile-filtered (0.22-μm filter) and kept in the dark at 4°C
before use. RPMI-1640 (Gibco/Invitrogen, Carlsbad, CA) was used as the basal medium for
cultures. All reagents except those noted were obtained from Sigma (St. Louis, MO).
Kubota’s medium (KM) was designed originally for hepatoblasts [21] and now has been
found effective for hHpSCs [13,14, 22]. It consists of any basal medium (here being RPMI
1640) with no copper, low calcium (0.3 mM), 10−9 M selenium, 0.1% BSA, 4.5 mM
nicotinamide, 0.1 nM zinc sulfate heptahydrate, 10−8 M hydrocortisone, 5 μg/ml transferrin/
Fe, 5 μg/mL insulin, 10 μg/mL high density lipoprotein, and a mixture of free fatty acids
that are added bound to purified human serum albumin. Details of its preparations are given
in a recent methods review [23].
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Preparation of Cell Suspensions and of Cultures
Cell Preparations—Cell suspensions of human fetal livers were prepared as described
previously [13, 23]. The original cell suspension is comprised of multiple parenchymal cell
populations [hHpSCs (~1–3%), hHBs (~80–82%), and committed progenitors (1–2%)] and
various non-parenchymal cells [endothelia, stellate cells, and hemopoietic cells (collectively
12–15%)]. Parenchymal cell aggregates were separated from floating non-parenchymal cells
by repeated slow spin centrifugation. The parenchymal cells were then subjected to another
round of collagenase digestion to yield a single cell suspension and resuspended in KM.
Stock parenchymal cell suspensions routinely had viabilities exceeding 98% on day 0 as
assessed by trypan blue exclusion analysis.
Culture selection of hHpSCs was done as described previously [23]. Approximately 3×105
cells were plated onto a 10-cm culture dish (cat# 08–771–24; Fisher Scientific, Pittsburgh,
PA) and in KM with 5% fetal bovine serum, FBS (cat# 26140–079, GIBCO, Carlsbad, CA).
After the cells attached (within a few hours), the medium was changed to serum-free KM
and further medium changes with serum-free KM occurred every 3 days. Colonies formed
within 3–5 days and were observed for up to 3 months. Each colony is comprised of
hHpSCs to which angioblasts are closely associated; the angioblasts give rise to hepatic
stellate cell precursors that are found just outside the perimeter of the colony [13,14, 24].
For the experiments, hHpSC colonies were picked by hand after 14–18 days using an
inverted microscope (1X-FLAIII; Olympus, Japan and Melville, NY). Representative
hHpSC colonies are shown in Fig 1d–f.
Mice and Rats—C57Bl/6 SCID/nod mice were purchased from Jackson Laboratories (Bar
Harbor, Maine) and Sprague Dawley rats from Charles River (Raleigh, NC). The mice were
housed in a barrier facility and the rats in a standard animal room on the campus of the
University of North Carolina-Chapel Hill (UNC-CH), NC. Animals received care according
to the Division of Laboratory Animal Medicine, UNC-CH guidelines, ones approved by
AALAC.
Transplantation of hHpSCs into Immunocompromised Hosts—Animals were
anesthetized with 40–85 mg/kg pentobarbital injected intraperitoneally (IP) and treated after
the “toe pinch” reflex displayed a pain-free state. For survival studies and post
transplantation, animals were given analgesics, Ketamine HCL (100mg/kg) mixed with
Xylazine (5–16 mg/kg), intraperitoneally (IP), and warmed under a heat lamp for 15 minutes
to assist in post-surgery recovery. An additional dose of Ketamine HCL and Xylazine IM
was administered 8 hours later. For studies not requiring survival of the animals, the animals
were anesthetized by IP injection and monitored until the “toe pinch” reflex displayed them
to be pain free. They were then immediately exsanguinated, and liver, lungs, kidneys, and
other tissues were dissected free and fixed with paraformaldehyde. The abdominal cavity
was opened; the aorta was cannulated and then clamped; and the portal vein was severed.
Then, 60mls of 1x phosphate buffered saline (PBS) was retro-flowed through the liver at 8
ml/minute to clear the liver of red blood cells before proceeding as described below.
Tissue Procurement from Transplanted Mice—After euthanasia, the liver was
removed, cut into 2 mm3 portions, and saturated in 30% sucrose 1x PBS. Tissues were then
embedded in Tissue-Tek O.C.T. Compound (Sakura), snap frozen utilizing a 100% ethanol
bath surrounded by liquid nitrogen, prepared for 5 μm thick frozen sections, and the sections
mounted on tissue culture slides. Routine examinations were made in some sections stained
with hematoxylin-eosin (H&E) and with the others for immunohistochemistry. In Fig. 1a-c
are shown representative sections of host livers transplanted with hHpSC cells.
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Immunohistochemistry: Paraffin Embedded Tissues—Serial sections (5 μm thick)
were prepared of formalin-fixed, paraffin-embedded livers from mice that were transplanted
with hHpSCs or from controls not transplanted with cells. The sections were incubated twice
in PBS with 0.3% Triton X-100 for 10 minutes and then in 0.3% hydrogen peroxide solution
in order to block endogenous peroxidase activity. The sections were then blocked with
serum and treated with an Avidin-Biotin blocking kit. This kit and associated reagents for
avidin-biotin staining are all from Vector Laboratories (Burlingame, CA). The blocking was
used to inhibit non-specific binding in the tissue and then incubated with primary antibody
overnight at 4 °C. Protease digestion using the Auto/Zyme Reagent Set (Biomeda, Foster
City, CA) was employed for CK-19 staining before blocking with serum. Sections were then
incubated with biotinylated secondary antibody and ABC reagents of the Vectastain Elite
Universal ABC kit according to the manufacturer’s instructions. The secondary antibody
was detected using the Avidin-Biotin-Peroxidase method with 3,3′-diaminobenzidine as the
substrate. Negative controls were performed by omitting the primary antibody and/or using
isotype control antibodies. These controls revealed minimal or no background staining (data
not shown).
Immunochemistry: Frozen Sections—Sections were fixed in 50/50 acetone-methanol
for 2 minutes, washed in PBS, and blocked with 10% goat serum for 45 minutes. The
sections were then exposed to primary conjugated human antibody at room temperature for
1-to-8 hours. Details of antibody concentrations are listed in Table 1.
Magnetic Beads—Magnetic bead immunoselection technologies make use of magnetic
beads coupled to a specific antigen antibody that are presented to cells [4]. In this study,
HEA-125 antibodies to EpCAM coupled to magnetic iron microbeads were obtained from
Miltenyi Biotech (Bergisch Gladbach, Germany, recently cataloged as CD326 Microbead).
The EpCAM antibody-microbead has an overall diameter of 50–100 nm, well within viral
particle size magnitudes of < 200 nm, and is a surface tagging agent that can be endocytosed
into the cell. Since the agent is a magnetic label, it is expected to enhance T2 and T2*
relaxations and lead to hypointensity or signal voids in MR spin echo or gradient echo scans.
Labeling the Cells with EpCAM-Magnetic Microbeads—Cells were exposed to an
EpCAM-microbead concentration of 10 μL EpCAM antibody/microbead per 107 cells in
100 μl buffer for 40 minutes at 4°C (Miltenyi Biotech, Bergisch Gladbach, Germany) using
KM as the buffer. After HEA-125 labeling, excess microbeads were washed from cells. If
the cells were on culture plastic, they were removed from the dishes mechanically and
transferred into 1% agarose gels. If the cells were in suspension, they were collected as
pellets after centrifuging at 250 revolutionary centrifugal force (RCF) for 5 min. Pelleted
cells were resuspended and seeded at 83,500 cells/cm2 onto dishes.
Label Confirmation—Twenty-four hours post labeling, the cultures were washed with 1x
PBS, and prepared for transmission electron microscopy (TEM) using a Zeiss LEO 910
TEM (Carl Zeiss, SMT, Germany and Thornwood, NY).), a Zeiss Supra 25 Field Emission
scanning electron microscopy, and a Kevex 7000 energy dispersive x-ray imaging system
(Noran System of Thermo Scientific, Waltham, MA). All are available in the Microscope
Services Facility at UNC (core director: Dr. Robert Bagnell). For TEM, the cultures were
fixed in a 0.1M sodium cacodylate solution with 3% glutaraldehyde and 0.05M CaCl2 at pH
7.4. For SEM and EDX, the cultures were washed with 1x PBS, fixed in a 0.15M sodium
phosphate solution with 3% glutaraldehyde at pH 7.4. For EDX, the hHpSCs were seeded
onto 0.4 μm culture inserts (cat #353493; Becton Dickinson, Franklin Lakes, NJ) for
improved EDX analysis.
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Aggregates of hHpSCs—3-Dimensional (3-D) aggregates of hHpSCs were generated
from cell stock suspensions by placing cells in culture dishes containing KM and placing the
dishes on Thermolyne Orbital Rotomix M71735 rocker platforms (Krackeler, Scientific,
Albany, NY). Platforms were placed inside an incubator (37°C, 5% CO2) and rockers
swayed at 10 rpm. Small aggregates were removed after a10-minute duration, while larger
aggregates were generated over 90-minute intervals. The radius, diameter, and area of the
harvested cell aggregates were determined with hematocytometer and phase contrast
imaging. Area measurements and volumetric extrapolations were made assuming a single
hHpSC has a radius of ~8 μm, and the descendents of hHpSCs, the hepatoblasts, have a
single cell radius of ~11 μm, findings supported in direct measurements done in prior
studies [13–15].
Pre-transplantation MRI—MR imaging was done at Duke University’s Center for In
Vivo Microscopy using a 7.0 T 21-cm horizontal bore Magnex magnet interfaced to a GE
EXCITE console (EPIC 12.4; GE Medical Systems). To analyze the efficiency of detecting
labeled cells by MRI, labeled and unlabeled cells were embedded in 1% agarose on 35 mm
petri dishes. Two-dimensional gradient echo (4.0 cm FOV, 15 ms TE, 250 ms TR, 30° flip
angle, 256 × 256 matrix size) and 3D spin echo images (0.5 mm slice thickness, 90° angle,
4.0 cm FOV, TR = 250 ms, TE = 15 ms, 4 averages) spanned the thickness of the tissue.
Cell aggregate diameters and areas were measured using known micrograph border
dimensions, either 4cm x 4cm or 5cm x 5cm. Agarose gels without any cells were used for
the calibrations.
Validation of MRI Detectability of Labeled Cells In Situ—To determine whether
labeled cells can be detected in situ, labeled and unlabeled hHpSCs were transplanted
directly into livers of Sprague Dawley rats and then immediately imaged. Labeled or
unlabeled hHpSCs (n = ~2E6) suspended in 70 μl of KM were transplanted into the liver
through portal vein catheterization. Since the livers were to be isolated for imaging (to
enhance the signal strength), a potential complication arises from the paramagnetic property
of deoxygenated blood. Consequently, the liver was perfused with 4% paraformaldehyde
containing Magnevist, gadopentetate dimeglumine (Berlex Imaging, Montville, N.J.) at a
20:1 liquid suspension to remove red blood cells and enhance T1 imaging. The organ was
then excised and kept in 4% paraformaldehyde. For MRI, the isolated livers were placed on
a 3.0 cm-diameter surface RF coil. Acquired images consisted of both 2D interleaved,
multislice gradient echo (0.5 mm slice thickness, 4.0 cm FOV, TR = 250 ms, TE = 15 ms, 4
averages) and 3D spin echo images (0.5 mm slice thickness, 90° angle, 4.0 cm FOV, TR =
250 ms, TE = 15 ms, 4 averages) that spanned the thickness of the tissue.
Post-Transplantation Labeling and MRI—For cell transplantation, 2E6 labeled or
unlabeled hHpSCs suspended in 70 μL KM were transplanted into the spleens of SCID/nod
mice by exteriorizing a small segment of spleen from the mouse’s left lateral side. The cells
were injected intra-splenically using a gastight syringe and RN series needles (Hamilton, cat
#1710 and #80427). Once transplanted, the spleen was repositioned within the peritoneum,
and the site sutured closed. In the study, 16 animals were used and divided into four groups
(each with n=4): 1) sham studies, in which the animals were subjected to mock surgery; 2)
controls injected with microbeads but without cells; 3) controls transplanted with unlabeled
cells; and 4) mice transplanted with labeled cells. On days 6 and 18, and for groups 1, 2, and
3, 15 μL of HEA-125 (EpCAM)-microbeads were mixed with 85 μl PBS solution and
infused into the circulatory blood stream via mouse tail vein injection. Eight hours post
infusion, the mice were sacrificed and perfusion fixed via left ventricle cardiac cannulation
in preparation for MRI. In group 4, because cells were pre-labeled prior to transplantation,
mice were not exposed to the 85 μL PBS-EpCAM-microbead solution, but they were fixed
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and MR imaged at the same times as groups 1, 2, and 3. For MR imaging, animals were
positioned within a 4.0 cm-diameter birdcage RF coil for tissue investigations and analyzed
as described above for the isolated livers. For confirmation the MRI images were of
transplanted human cells, the livers were prepared for immunohistochemical analyses as
described above.
Data Analyses—All experiments were repeated with suspensions of hHpSCs from at least
three independent tissue isolations, with triplicate measurements per experiment. All data
sets were plotted using Sigma Plot (SPSS Science) or Microsoft Excel (Microsoft, Redmond
WA), where each graph’s error bars indicate ± one standard deviation.
Results
Epithelial Cell Adhesion Molecule, EpCAM, is a Surface Marker on hHpSCs
Transplantation of EpCAM+ cells into SCID/nod mice resulted initially in cells clustered
near the central veins and detectable with antibodies to human albumin (Fig 1a). The
hHpSCs do not express AFP [13], but after transplantation into the livers of the murine
hosts, they expanded and matured within a few days to hepatoblasts with strong expression
of human AFP (Fig 1c). In studies reported elsewhere, longer periods of time in vivo
resulted in fully mature human liver cells [13]. Fig. 1b is an image of a liver section stained
with an isotope control antibody.
In cultures, the hHpSCs undergo clonogenic expansion on plastic and in serum-free KM
(Fig 1. d–f). The hHpSCs strongly express EpCAM (green labeling in Fig. 1e and 1f) and
also NCAM (red staining of cells in Fig. 1f). The nuclei are visible by staining with 4′, 6-
diamidino-2-phenylindole (DAPI) (Fig. 1d–f).
Labeling of hHpSCs with Magnetic Microbeads Tagged with EpCAM Antibody
Magnetic beads are available in varying sizes, but those found especially useful are very
small beads that are the size of viral particles (50–100 nm). Access of such particles to
tissues will vary with the 3 known categories of capillaries comprised of 1) continous
capillaries (skeletal muscle, heart, skin), 2) fenestrated capillaries (intestinal mucosa,
endocrine and exocrine glands, kidney), and 3) discontinuous capillaries (reticulo-
endothelial tissues including the liver, bone marrow and spleen). The width of inter-
endothelial gaps (also called clefts) in continous capillaries are 20–60 Å and accommodate
only ions and water; those in fenestrated capillaries are ~60–80 nm and allow small
molecules and some proteins; and those in reticulo-endothelial cells are 30–40 μm and allow
hemopoietic cells and large molecules. In addition, in all 3 categories, there are endothelial
cell pores, called “fenestrae”, of two sizes, the larger one being 200–300 Å and that
accommodate transport of molecules of varying size across the endothelia cell [25].
Schematics depicting cell-bead-MRI relations are shown in Fig 2 on which is a
representative bead (Fig 2a) and its attachment to cells via antibodies (Fig 2b).
The internalization and surface attachment of HEA-125 (EpCAM) microbeads into/onto
hHpSCs was confirmed by transmission electron microscopy (TEM) and scanning electron
microscopy (SEM) analyses on cultured cells (Fig 3). Control images for both TEM and
SEM consisted of unlabeled cells. The experimental groups consisted of hHpSCs labeled
with EpCAM microbeads. The high magnification (2000x) TEM micrograph shown in Fig
3a displays a heterogeneous distribution of 80 nm diameter glycogen particles throughout
the cell’s interior, seen as gray and black dotted specks. The detail Fig 3b (31500x image)
further displays the spheroid structure of glycogen. Glycogen’s dark contrast and size can
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cause it to interfere with recognition of microbead-labeled cells and single contrast agents
50–100 nm in size. For contrast-labeled cells, as shown in Fig 3c and 3d, glycogen is again
seen within the cells interior. As shown in both figures, several large particles having ~222
nm diameters are observed in the cell’s interior. These particles are much larger than those
for glycogen or individual EpCAM microbeads (e.g. 50nm <×<100nm) and are due to
aggregation of microbeads.
Further characterization of EpCAM microbeads on cells is shown with the SEM
micrographs in Fig 3e-i. A SEM control, Fig 3e, illustrates two hHpSCs in close physical
contact and without labeling with EpCAM microbeads. The cells’ surfaces are fairly smooth
and absent of irregularities caused by microbead surface attachments. Contrastingly, Fig 3f
shows a contrast-labeled cell with large numbers of EpCAM microbeads on the left lateral
cell surface (arrows). Further illustrations of these microbeads are shown in Fig 3g-i in
which cells labeled with EpCAM microbeads and viewed at increasing image
magnifications. Figure 3g displays large clumps of microbead aggregates. Figure 3h
illustrates enhanced microbead detail with many intertwined beads connected to form a
“web mesh” on the cell’s surface. Figure 3i illustrates EpCAM microbeads clustered on cell
surfaces with detectable diameters ranging from 100 nm (smallest) to 500nm (medium) to
4166 nm (large) magnitudes.
To confirm that the imaged particles are the EpCAM magnetic microbeads, energy
dispersive x-ray imaging system (EDX) was used to provide a “snapshot” view of the
microbeads atomic structure, as displayed in the line graph in Fig 3j. As the graph shows,
multiple peaks over a 0–10 KeV range are distinctly labeled. The peak for Fek iron (Fe) as
determined by K-shell valance electron removal (kα) at 6.3 KeV, indicates that the
microbeads contain iron. Other components include magnesium (Mg), aluminum (Al),
silicone (Si), and silver (Ag). The white specks in Fig 3j are illustrative of EDX signals
associated with microbead-labeled cultured cells.
MRI of hHpSCs in Agarose Gels
Representative MR images of agarose-embedded cells, with and without labeling, are shown
in Fig 4, including 1) gel only without cells, 2) gel with unlabeled cells, and 3) gels with
labeled cell aggregates. For the agarose-only control (Fig 4a), the image depicts a relatively
homogeneous light gray background. Few MR signal irregularities were observable,
including background intensity nonuniformity due to RF coil magnetic field inhomogeneity
(e.g. lower quarter of the FOV) and intensity voids arising from large (e.g., lower left side of
the dish marked by ⇓) and miniscule air bubbles (↑ or ↓) that developed during agarose
gelation. The MRI appearance of the agarose gel containing unlabeled cell aggregates (Fig
4b) is similar to that of the agarose-only control. In contrast, agarose gel containing
EpCAM-nanoparticle-labeled cell aggregates (Fig 4c) has conspicuous large clusters of
signal voids of varying sizes, attributed to cell aggregates of varying sizes that are labeled
with paramagnetic iron oxide contrast agents.
Quantitative Spheroid Formations Analyzed by Microscopy and MRI Normalizations
To provide a basis for estimating the number of cells in aggregates detected in MR images,
the aggregate radii were measured by microscopy using a hemocytometer grid (200 μm
grid), categorized with respect to appropriate headings (e.g. small, medium, and large) and
compared against MR signals from labeled cells (Fig 5). Some measurement variability is
acknowledged as individual cell radii are heterogeneous in size with variations being
associated with cell sourcing, microscopy optics, and image overlay thresholds. The
numbers of cells in selected aggregates were determined by microscopy and correlated to the
aggregate volumes estimated from their radii, assuming a spherical shape. For example, a
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cell count of 120 was found for an aggregate of 33 μm radius, or 1.5E5 μm3 volume. Linear
regression of the cell count versus aggregate volume yielded the relationship,
(1)
where N is the cell count and Vmicroscopy is the aggregate volume in μm3.
Moreover, the radii of some cell aggregates measured from microscopy and MR images
were correlated (Fig. 6) resulting in the relationship,
(2)
with rMRI and rmicroscopy representing the MRI and microscopy measured cell aggregate
radii, respectively. The cell aggregate radii showed a very strong correlation, with
correlation r2 = 0.99. Not surprisingly, the cell aggregates appeared larger (64% in this case)
in MRI than in actuality, since the influence of the magnetic beads that give rise to the MRI
contrast extends beyond their physical boundary. Based on Eq. (1) and (2), the cell count N
in terms of MRI-observed aggregate radius rMRI is estimated to be,
(3)
Alternatively, for instances when the cell aggregates are clearly non-spherical, Eq. (2) is
used to convert Eq. (1) into,
(4)
where VMRI is the volume of the MRI region-of-interest.
Equations (3) and (4) were used to directly compute the cell count based on MRI observed
aggregate size in all subsequent analysis, with the caveat that it represents only a first-order
approximation, given all factors and assumptions involved.
MRI Detection and Quantification of Labeled Cells In Situ
MR images of labeled cells injected into whole livers in 3 animals are shown in Fig. 7,
which clearly demonstrates the detectability of the labeled cells. Fig 7a1 illustrates two liver
lobes with intensity voids corresponding to aggregates of labeled cells throughout the
tissues. For analysis, a polygonal region of interest was segmented on the region containing
relatively high concentration of signal voids. The intensity of the region was inverted and
then thresholded to obtain a binary image that better shows the locations and sizes of the
labeled cell aggregates (Fig 7a2). Comparable MRI and cell aggregate binary images
obtained for the other 2 animals are shown in Figs 7b1, 7c1, 7b2 and 7c2, respectively.
Further analyses of the binary images revealed that the labeled cell aggregates across all 3
animals have average radius of 133.4 μm, which, based on Eq. (3), corresponds to an
average cell count of 1.1 × 102.
Post-Transplantation Cell Labeling, Detection and Quantification
Selected 2D MR image slices of the post-transplantation cell labeling study are shown in
Fig. 8. For the controls, Figs. 8a-c illustrate adequately perfused liver lobes appear as
homogeneous backgrounds except for the hyperintense branching pathways near the liver
center that correspond to the hepatic sinusoids. Intensity voids that signify labeled cell
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aggregates are clearly absent. This confirms the lack of contrast from the microbeads each of
the 3 control groups, which include hosts not injected with human cells, hosts injected only
with microbeads, and hosts injected with unlabeled hHpSCs. Figures 8d and 8e show
representative MRI images of hosts originally injected with unlabeled hHpSCs but
subsequently were given magnetic microbeads on day 6 and 18, respectively, after
transplantation. At least 2 and 5 hypointense foci that indicate the presence of hHpSC
aggregates can be detected in the day 6 and 18 MR image slices, respectively. Although the
relative locations of cell aggregates are not conspicuous in the day-6 image slice, those in
the day-18 image slice are clearly located near large sinusoidal pathways of the liver, which
is consistent with the fact that cells were transplanted into the liver via the portal vein and
must migrate through sinusoidal pathways before integrating into the liver tissue.
Examinations of all image slices obtained for the hosts labeled at day 6 and 18 detected the
presence of a total of 4 and 7 hHpSC aggregates, respectively. Using the quantification
technique described above, the cell counts for the aggregates found in sites 1 and 2 of the
day-6 image slice shown in Fig. 8d are approximately 1065 and 128, respectively. The two
additional aggregates detected were determined to have approximately 289 and 527 cells.
Similarly, the cell counts in sites 1 – 5 of the day-18 image slice (Fig. 8e) are 1.1 × 104, 4.4
× 103, 260, 7.8 × 103 and 4.3 × 103, respectively. The two additional aggregates detected
were determined to have approximately 6.2 × 103 and 6.0 × 103 cells. Although these cell
counts are estimates, the facts that more aggregates are found and that most aggregates have
markedly higher cell count in day-18 than in day-6 are indicative of post-transplantation cell
proliferation.
DISCUSSION
We demonstrate a novel method for MRI tracking of transplanted human hepatic stem/
progenitors (hHpSCs and hHBs) by labeling the cells in situ with magnetic microbeads
coupled to an antibody binding to a surface antigen on the transplanted cells. The first
antigen used to establish the technique has been human EpCAM, found in human livers
uniquely on hHpSCs, hHBs and other hepatic progenitors [13,14], on liver cancer stem cells
that are transformants of a subpopulation(s) of the hepatic stem/progenitors [26], and on
proliferating epithelial cells in other tissues [27–29]. The method is applicable to any surface
antigen for which antibody-magnetic microbeads are available. Existing methods for
tracking transplanted cells are either non-specific, require marking the cells prior to
transplantation, are effective only for short-term studies, or potentially can harm the cells.
One of the most established techniques is to mark the cells with magnetic beads (particles,
nanoshells) that become incorporated into cells by endocytosis [4, 30–33]. The ability to
mark the cells is dependent on their propensity to endocytose the magnetic beads or
nanoshells. The uptake of magnetic particles can be made more efficient by the use of
electroporation [34]. However, all labeling strategies dependent on endocytosis offer little
specificity as to which cells become marked. Similar problems occur for cells marked by
perfluorocarbon nanobeacons [35] and with TAT-peptide derivatized nanoparticles [5], or
with contrast agents [4, 30, 36]. Stable labeling of a specific cell population, such as by
transfection of a gene, is highly successful and widely used for experimental studies [36,37],
but is not suitable for clinical programs given that transfected cells can give rise to tumors
depending on the integration site [38].
The newest strategies reported are ones in which magnetic resonance spectroscopy are
focused on metabolomic profiling of unique subpopulations such as stem/progenitor cells
[40] and offer a way to monitor endogenous and transplanted cells via unique metabolomic
features detectable by MR spectroscopy [20, 41]. This approach does not distinguish
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transplanted versus endogenous cells unless the transplanted cells are in a tissue site distinct
from that of the endogenous cellular subpopulations.
Contrast agents, such as Gadolinium-DTPA complex or SPIO-based colloids, facilitate
visibility and display more intense MR signals, but these also do not have specificity
[36,42,43]. Signal agents can range from iron metabolites (e.g. deoxygenated blood), to
paramagnetic structures (copper, manganese), to superparamagnetic structures (iron oxide)
that can target receptors through iron oxide surface modifications [43]. Each agent modifies
either T1, T2, or T2* relaxation decays for signal contrast. The use of such nonspecific
labeling has proven effective but limiting, because cells of interest are isolated, ex vivo
labeled, transplanted and then imaged before contrast labels detach. Detachment can be
either by physical dislodgement or by chemical secretion. Viable cells strive for homeostasis
and efficiently remove foreign particles from their microenvironments obviating the use of
this approach for long-term studies.
We demonstrate a method that can be used in experimental and clinical programs and that
can identify cells that can be labeled before or after transplantation. Moreover, transplanted
cells can be monitored in the same host again and again by injection of the label just prior to
MR imaging (Fig 8) negating the need for long-term contrast attachment and eliminating
uncertainties of contrast decay. In vivo labeling with antibodies to specific surface markers
and tagged to magnetic microbeads makes possible the imaging of specific subpopulations
of cells with defined antigenic profiles.
Being able to visualize the target population against the background of other cells will vary
with the antigen chosen. We were able to limit the background by using xenogeneic
transplants of human hepatic progenitors into immunocompromised murine hosts and using
an antigen, EpCAM, expressed only by the human cells [13, 14, 19]. Targeting EpCAM
should work also for transplantation into human livers given that the only cells in the liver
that express it are hHpSCs and hHBs, both located adjacent to the portal triads of the liver
acinus. These progenitor subpopulations constitute a small percentage (<1–2%) of the
parenchymal cell populations in pediatric and adult livers. Achieving visibility of a target
population by MRI will be straight forward if the target population is antigenically distinct
from the surrounding cells such as what would occur with cancer cells, other types of
mutated cells, or cells damaged by disease or other insults [26, 27, 44, 45].
The EpCAM-microbeads, with diameters smaller than viruses (<200nm), were able to
traverse through the host’s circulatory system and capillary beds to adhere to transplanted
cells expressing the antigen (Fig 8). Immunohistochemistry to detect human-specific
proteins in sections of the livers confirmed the MRI findings (Fig 1). At day 18, labeled
aggregates were found near sinusoids (Fig. 8). In vivo MR comparisons between day 6 and
18 signals illustrate cell growth as day 18 images confirm up to 12 times more cells than on
day 6.
Cell therapies are becoming medical treatment options to support patients with diseased
organs or to assist with tissue regeneration. However, to assess more rigorously the potential
of cell therapies and of any particular method of transplantation, it is necessary to label
specific cell types and non-invasively track cells after inoculation, and to follow the location
and expansion of the cells thereafter. In this work, labeling of human hepatic progenitors has
been verified by in vitro, ex vivo, and in vivo MR signal patterns and correlated with in vivo
responses for up to 18 days. These imaging studies confirm in vivo cell tracking of
transplanted human hepatic cells is plausible and is a strategic method that can be used to
improve methods for transplantation for any form of cell therapy including stem cell
therapies.
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An alternative use for the method is to diagnose and to follow patients with primary or
metastatic tumors, now known to be comprised of mutated stem/progenitor populations with
antigenic profiles distinct from those of mature cells [44, 45]. Antigens found on the tumors
can be targeted with an antibody bound to microbeads and followed by patient imaging.
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EpCAM Epithelial cell adhesion molecule
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(a–c) Sections of livers of SCID/nod mice transplanted with hHpSCs and sacrificed at day 7
after transplantation and stained either for human albumin (a) or human alpha-fetoprotein
(c). As a control, a section of liver from a transplanted mouse was stained with an isotype
control for alpha-fetoprotein (b). Antibodies to human albumin demonstrated some cross-
reactivity with murine albumin resulting in less distinction between host cells and
transplanted cells. Nevertheless, there is sufficient distinction enabling the recognition of the
colony of human cells within the host liver cells. (d–f) Colonies of human hepatic stem cell
(hHpSCs) showing expression of epithelial cell adhesion molecule, EpCAM, present
throughout the cells and especially at the cell surface. In all of them the nucleus is stained
with DAPI=blue. (d) Digital interference contrast images with DAPI staining providing a
higher magnification of an hHpSCs colony; (e) Immunohistochemistry of the hHpSC colony
for EpCAM (green); (f) Immunohistochemistry of the hHpSC colony for EpCAM (green)
and NCAM (red).
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Schematics demonstrating the principle of contrast labeling cells for MR imaging. (a)
Schematics of the magnetic microbeads coupled to an antibody. (b) Schematic of
microbeads bound to a human hepatic stem cell, hHpSC. (c) Schematic to explain the
enhancement of MRI by use of the microbeads.
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Transmission Electron Microscopy (TEM, a–d), Scanning Electron Microscopy (SEM, e–i),
and Emission Dispersive X-ray (EDX, Line graph and j) displaying human cells labeled
with HEA-125 antibodies coupled to magnetic microbeads (Miltenyi). (a–d) Ability to
detect the microbeads, and to distinguish them from glycogen particles (small arrows)
occurs with aggregates yielding a size above 200 μm (large arrows); (e) SEM of hHpSCs
that is not labeled with the beads; (f-iI) SEM of hHpSCs labeled with the beads (arrows
denote the beads); (j) The line graph is from EDX analyses and shows that the beads on the
cells contain the elements known to be in the EpCAM-microbeads, notably iron.
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MRI signals from agarose gel-embedded hHpSCs and hHBs labeled with the magnetic bead-
coupled to EpCAM antibodies. (a) Agarose gel only (no cells or beads); (b) Agarose gel
with unlabeled cells; (c) Agarose gel with labeled cells.
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Image cell aggregates as seen in microscopy and compared to their MRI appearances. Three
columns are labeled ‘Cell Parameters’, ‘Microscopy’, and MRI. Cell parameters depict
known cell aggregate measurements as confirmed by microscopic analyses and
hemacytometer calibrations. The intensities of the MR images have been scaled and
thresholded to enhance contrast, which explains the irregular shapes of the agarose gels.
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Correlation of cell aggregate sizes as observed in MRI and actually measured via
microscopy. Linear regression (solid line) indicates that the cell aggregates appear 64% (r2 =
0.99) larger in MRI than their actual sizes.
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In Vivo MR images from rat liver lobes inoculated with labeled cells. Panels a, b, and c
illustrate liver lobes heterogeneously inundated with labeled cell aggregates. Dense cell
signals are highlighted in Panels a1, b1, and c1; the same signals are threshold imaged in
Panels a2, b2, and c2.
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In vivo MR images of unlabeled and contrast labeled hHpSCs in SCID/nod mice. Signal
voids indicating the presence of magnetically labeled hHpSC aggregates are absent in the
control groups, which include animals that (a) were not transplanted with hHpSCs and did
not receive microbeads, (b) were not transplanted with hHpSCs but received microbeads,
and (c) were transplanted with hHpSCs but not with microbeads. In contrast, labeled cell
aggregates were detected in animals that received hHpSCs and given microbeads at (d) day
6 or (e) day 18 post-transplantation. The enumerated sites correspond to signal voids
selected for quantitative analysis and reported in the text.
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Table 1
Antibodies utilized in labeling hHpSCs
Company Product
Becton Dickenson NCAM (CD56), 1:250 (BD# 340363); ICAM-1 (CD54) 347977); Conjugated isotype controlsMouse IgG FITC and PE
(#349041 and 349043)
Myltenyi BIotec mouse anti-human EpCAM, 1:200
Neomarkers EpCAM, 1:750 (# MS-155-P1ABX)
NovaCastra CK19, 1:300 and 1:100 (#NCL-CK19)
Sigma Albumin, 1:1200 (# A6684); AFP, 1:250; NCAM (CD56), 1:250 (#C9672)
Zymed AFP (# 18–0003); CK8/18, 1:1000 (# 18–0213)
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